FBLG (FibroBiologics Inc.) stock: $0.94, $6.4M market cap, $3.5M cash, $2.9M EV, $22.4M fully diluted market cap. Next expected readout: Dec-26. Lead program: SoC (Diabetic Foot Ulcer (DFU)), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Topically administered allogeneic fibroblast cell-based therapy for wound healing. 12-week Phase 1/2 trial in Australia (sponsored by FibroBiologics Australia Pty Ltd) began screening/enrolling/dosing in Q2 2026; enrollment slower than anticipated.
Status note Intravenously administered allogeneic fibroblast spheroid therapy for psoriasis. IND-enabling preclinical studies complete; Phase 1/2 IND application filed with FDA Dec 30, 2025.
CYMS101
Phase 1 · ActiveModality: fibroblast cell therapy
Indications
Multiple sclerosis(Phase 1)
Status note Intravenously administered allogeneic fibroblast single-cell/spheroid therapy for MS. Completed Phase 1 study in Mexico.
Status note Intradiscal allogeneic fibroblast cell-based therapy for intervertebral disc/articular cartilage repair. FDA IND clearance received in 2018, conditional on master cell bank approval.
Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.